1-Alkylcarbonyl-5-fluorouracil prodrugs: Synthesis, thermal and hydrolytic stability

Drug Development and Industrial Pharmacy

Volumn 22, Issue 2, 1996, Pages 85-90

  Beall, H D ^a   Prankerd, R J ^a   Sloan, K B ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 ACETYL 5 FLUOROURACIL; 1 BUTYRYL 5 FLUOROURACIL; 1 HEXANOYL 5 FLUOROURACIL; 1 OCTANOYL 5 FLUOROURACIL; 1 PROPIONYL 5 FLUOROURACIL; 1 VALERYL 5 FLUOROURACIL; FLUOROURACIL; FLUOROURACIL DERIVATIVE; FORMALDEHYDE; PRODRUG; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG STABILITY; DRUG SYNTHESIS; HYDROLYSIS; INFRARED SPECTROSCOPY; PH; PROTON NUCLEAR MAGNETIC RESONANCE; THERMOSTABILITY; ULTRAVIOLET SPECTROSCOPY;

EID: 0029983211     PISSN: 03639045     EISSN: None     Source Type: Journal    
DOI: 10.3109/03639049609041976     Document Type: Article

References (23)

1. C. J. Dillaha, G. T. Jausen, W. M. Honeycutt, and C. A. Holt, Arch. Dermatol., 88, 247 (1963).
2. C. J. Dillaha, G. T. Jansen, W. M. Honeycutt, and C. A. Holt, Arch. Dermatol., 92, 410 (1965).
3. T. Tsuji and T. Sugai, Arch. Dermatol., 105, 208 (1972).
4. E. Epstein, Arch. Dermatol., 121, 207 (1985).
5. E. Touitou and L. Abed, Int. J. Pharm., 27, 89 (1985).
6. M. Goodman and B. W. Barry, J. Invest. Dermatol., 91, 323 (1988).
7. H. Beall, R. J. Prankerd, and K. B. Sloan, Int. J. Pharm., 111, 223 (1994).
8. K. B. Sloan, J. J. Getz, H. D. Beall, and R. J. Prankerd, Int. J. Pharm., 93, 27 (1993).
9. B. Mollgaard, A. Hoelgaard, and H. Bundgaard, Int. J. Pharm., 12, 153 (1982).
10. K. B. Sloan, E. F. Sherertz, and R. G. McTiernan, Int. J. Pharm., 44, 87 (1988).
11. A. Buur and H. Bundgaard, Int. J. Pharm., 21, 349 (1984).
12. M. Tada, Chem. Lett., 129 (1975).
13. H. D. Beall, R. J. Prankerd, L. J. Todaro, and K. B. Sloan, Pharm. Res., 10, 905 (1993).
14. H. D. Beall, Bioreversible derivatives of 5-fiuorouracil (5-FU): Improving dermal and transdermal delivery with prodrugs, Ph.D. dissertation, University of Florida, Gainesville, December 1991.
15. N. Bodor, K. B. Sloan, Y. Kuo, and T. Higuchi, J. Pharm. Sci., 67, 1045 (1978).
16. A. Streitwieser, C. H. Heathcock, and E. M. Kosower, Introduction to Organic Chemistry, 4th ed., Macmillan Publishing Co., New York, 1992, p. 522.
17. M. Charton, in Design of Biopharmaceutical Properties Through Prodrugs and Analogs, E. B. Roche, ed., American Pharmaceutical Association, Washington, D.C., 1977, p. 228.
18. A. Buur, H. Bundgaard, and E. Falch, Int. J. Pharm., 24, 43 (1985).
19. O. Exner, Correlation Analysis of Chemical Data, Plenum Press, New York, 1988, p. 154.
20. R. F. Hudson and G. E. Moss, J. Chem. Soc., 5157 (1962).
21. V. Gold, Trans. Faraday Soc., 44, 506 (1948).
22. K. B. Sloan, H. D. Beall, W. R. Weimar, and R. Villanueva, Int. J. Pharm., 73, 97 (1991).
23. H. A. Staab, Angew. Chem. Int. Ed. Engl., 1, 351 (1962).